SpringerLink
Log in

The Prediction of Recurrence in Low-Risk Endometrial Cancer: Is It Time for a Paradigm Shift in Adjuvant Therapy?

  • Review
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Five to 10% of patients with stage IA, grade 1 or 2, endometrioid adenocarcinoma subsequently develop locoregional or distant recurrence. These patients have significantly reduced 5-year survival rates and salvage therapy success rates as low as 40%. The aim of this review is to highlight knowledge gaps that could further refine the risk categories of endometrial carcinoma (EC) and guide future randomized trials of adjuvant therapy for low-risk EC. A systematic search of the literature on PubMed and Medline was conducted using the following search terms: endometrial cancer, endometrial adenocarcinoma, endometrioid adenocarcinoma, low grade, early stage, stage IA, low risk, locoregional recurrence, and relapse. Relevant primary studies were extracted and included in this review. Risk factors for recurrence of low-risk EC were epidemiological (age, body mass index, ethnicity), molecular (DNA MMR, MSI, TP53 mutation and P53 defect, CTNNB1 mutation, PTEN and POLE mutation, L1CAM expression), pathological (positive peritoneal cytology, lymphovascular invasion, tumor size), and others like Ki67-percentage, micro-RNA expression, and hormonal receptor expression. CTNNB1 mutation, L1CAM expression, lymphovascular invasion, and tumor size were identified as significant risk factors for recurrence in low-risk EC. There are subsets of low-risk EC patients at high risk of recurrence and should be suspected when having the following risk factors: positive molecular markers, large tumor size, and lymphovascular invasion. A novel scoring system and randomized controlled trials should be conducted to identify these patients who will benefit most from adjuvant therapy to avoid recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zhang S, Gong TT, Liu FH, Jiang YT, Sun H, Ma XX, et al. Global, regional, and national burden of endometrial cancer, 1990-2017: results from the Global Burden of Disease Study, 2017. Front Oncol. 2019;9:1440. Published 2019 Dec 19. https://doi.org/10.3389/fonc.2019.01440.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–7.

    Article  CAS  Google Scholar 

  3. Keys HM, Roberts JA, Brunetto VL, the Gynecologic Oncology Group, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.

    Article  Google Scholar 

  4. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094–108. https://doi.org/10.1016/S0140-6736(15)00130-0.

    Article  PubMed  Google Scholar 

  5. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(21):1625–34. https://doi.org/10.1093/jnci/djs374.

    Article  PubMed  Google Scholar 

  6. Beavis AL, Yen TT, Stone RL, Wethington SL, Carr C, Son J, et al. Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: is there a role for chemotherapy? Gynecol Oncol. 2020;156(3):568–74. https://doi.org/10.1016/j.ygyno.2019.12.028.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Danish Gynecological Cancer Group. Chemotherapy or observation in stage I-II intermediate or high risk endometrial cancer. ClinicalTrials.gov Identifier: NCT01244789 [Internet]. Copenhagen: Danish Gynecological Cancer Group. 2018 [cited 2021 Jan 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT01244789

  8. Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer. 2010;46(13):2422–31. https://doi.org/10.1016/j.ejca.2010.06.002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Boothe D, Williams N, Odei B, Poppe MM, Werner TL, Suneja G, et al. The addition of adjuvant chemotherapy to radiation in early-stage high-risk endometrial cancer: survival outcomes and patterns of care. Int J Gynecol Cancer. 2017;27(5):912–22. https://doi.org/10.1097/IGC.0000000000000963.

    Article  PubMed  Google Scholar 

  10. SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, et al. Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol. 2014;134(2):393–402. https://doi.org/10.1016/j.ygyno.2014.06.003.

    Article  Google Scholar 

  11. Xu Y, Burmeister C, Hanna RK, Munkarah A, Elshaikh MA. Predictors of survival after recurrence in women with early-stage endometrial carcinoma. Int J Gynecol Cancer. 2016;26(6):1137–42. https://doi.org/10.1097/IGC.0000000000000733.

    Article  PubMed  Google Scholar 

  12. Bendifallah S, Ouldamer L, Lavoue V, Canlorbe G, Raimond E, Coutant C, et al. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: results from the FRANCOGYN study Group. Gynecol Oncol. 2017;144(1):107–12. https://doi.org/10.1016/j.ygyno.2016.10.025.

    Article  PubMed  Google Scholar 

  13. Topfedaisi Ozkan N, Meydanlı MM, Sarı ME, Demirkiran F, Kahramanoglu I, Bese T, et al. Factors associated with survival after relapse in patients with low-risk endometrial cancer treated with surgery alone. J Gynecol Oncol. 2017;28(5):e65. https://doi.org/10.3802/jgo.2017.28.e65.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Francis SR, Ager BJ, Do OA, Huang YHJ, Soisson AP, Dodson MK, et al. Recurrent early stage endometrial cancer: patterns of recurrence and results of salvage therapy. Gynecol Oncol. 2019;154(1):38–44. https://doi.org/10.1016/j.ygyno.2019.04.676.

    Article  PubMed  Google Scholar 

  15. Stasenko M, Feit N, Lee SSK, Shepherd C, Soslow RA, Cadoo KA, et al. Clinical patterns and genomic profiling of recurrent ‘ultra-low risk’ endometrial cancer. Int J Gynecol Cancer. 2020;30(6):717–23. https://doi.org/10.1136/ijgc-2020-001241.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kim SR, Pina A, Albert A, McAlpine JN, Wolber R, Gilks B, et al. Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. Int J Gynecol Cancer. 2020;30(6):783–8. https://doi.org/10.1136/ijgc-2019-000910.

    Article  PubMed  Google Scholar 

  17. Sozzi G, Uccella S, Berretta R, Petrillo M, Fanfani F, Monterossi G, et al. Tumor size, an additional risk factor of local recurrence in low-risk endometrial cancer: a large multicentric retrospective study. Int J Gynecol Cancer. 2018;28(4):684–91. https://doi.org/10.1097/IGC.0000000000001223.

    Article  PubMed  Google Scholar 

  18. Wang CJ, Chao A, Yang LY, Hsueh S, Huang YT, Chou HH, et al. Fertility-preserving treatment in young women with endometrial adenocarcinoma: a long-term cohort study. Int J Gynecol Cancer. 2014;24(4):718–28. https://doi.org/10.1097/IGC.0000000000000098.

    Article  PubMed  Google Scholar 

  19. Park JY, Seong SJ, Kim TJ, Kim JW, Kim SM, Bae DS, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol. 2013;121(1):136–42. https://doi.org/10.1097/aog.0b013e31827a0643.

    Article  PubMed  Google Scholar 

  20. Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer. 2013;49(4):868–74. https://doi.org/10.1016/j.ejca.2012.09.017.

    Article  CAS  PubMed  Google Scholar 

  21. Ureyen I, Karalok A, Turkmen O, Kimyon G, Akdas YR, Akyol A, et al. Factors predicting recurrence in patients with stage IA endometrioid endometrial cancer: what is the importance of LVSI? Arch Gynecol Obstet. 2020;301(3):737–44. https://doi.org/10.1007/s00404-019-05418-z.

    Article  CAS  PubMed  Google Scholar 

  22. Ayhan A, Şahin H, Sari ME, Yalçin I, Haberal A, Meydanli MM. Prognostic significance of lymphovascular space invasion in low-risk endometrial cancer. Int J Gynecol Cancer. 2019;29(3):505–12. https://doi.org/10.1136/ijgc-2018-000069.

    Article  PubMed  Google Scholar 

  23. Güngördük K, Firat Cüylan Z, Kahramanoglu I, Oge T, Akbayir O, Dede M, et al. Risk factors for recurrence in low-risk endometrial cancer: a case-control study. Oncol Res Treat. 2018;41(7-8):466–70. https://doi.org/10.1159/000488112.

    Article  PubMed  Google Scholar 

  24. Yoney A, Yildirim C, Bati Y, Unsal M. Low risk stage I endometrial carcinoma: prognostic factors and outcomes. Indian J Cancer. 2011;48(2):204–10. https://doi.org/10.4103/0019-509X.82895.

    Article  CAS  PubMed  Google Scholar 

  25. Han KH, Kim HS, Lee M, Chung HH, Song YS. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB. Medicine (Baltimore). 2017;96(21):e6976. https://doi.org/10.1097/MD.0000000000006976.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kommoss F, Kommoss F, Grevenkamp F, Bunz AK, Taran FA, Fend F, et al. L1CAM: amending the “low-risk” category in endometrial carcinoma. J Cancer Res Clin Oncol. 2017;143(2):255–62. https://doi.org/10.1007/s00432-016-2276-3.

    Article  CAS  PubMed  Google Scholar 

  27. de Foucher T, Sbeih M, Uzan J, et al. Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer. J Transl Med. 2018;16(1):131. Published 2018 May 21. https://doi.org/10.1186/s12967-018-1515-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Park JY, Seong SJ, Kim TJ, Kim JW, Bae DS, Nam JH. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer. Gynecol Oncol. 2017;146(1):39–43. https://doi.org/10.1016/j.ygyno.2017.05.002.

    Article  CAS  PubMed  Google Scholar 

  29. Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, et al. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol. 2019;153(3):517–20. https://doi.org/10.1016/j.ygyno.2019.03.100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Costigan DC, Dong F, Nucci MR, Howitt BE. Clinicopathologic and immunohistochemical correlates of CTNNB1 mutated endometrial endometrioid carcinoma. Int J Gynecol Pathol. 2020;39(2):119–27. https://doi.org/10.1097/PGP.0000000000000583.

    Article  CAS  PubMed  Google Scholar 

  31. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Abdel Azim S, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation [published correction appears in. J Natl Cancer Inst. 2013;105(15):1142–50. https://doi.org/10.1093/jnci/djt144.

    Article  PubMed  Google Scholar 

  32. Matsuo K, Yabuno A, Hom MS, Shida M, Kakuda M, Adachi S, et al. Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer. Gynecol Oncol. 2018;149(2):301–9. https://doi.org/10.1016/j.ygyno.2018.02.012.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Ørtoft G, Lausten-Thomsen L, Høgdall C, Hansen ES, Dueholm M. Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study. J Gynecol Oncol. 2019;30(5):e84. https://doi.org/10.3802/jgo.2019.30.e84.

    Article  PubMed  PubMed Central  Google Scholar 

  34. dos Reis R, Burzawa JK, Tsunoda AT, Hosaka M, Frumovitz M, Westin SN, et al. Lymphovascular space invasion portends poor prognosis in low-risk endometrial cancer. Int J Gynecol Cancer. 2015;25(7):1292–9. https://doi.org/10.1097/IGC.0000000000000490.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Bendifallah S, Canlorbe G, Raimond E, Hudry D, Coutant C, Graesslin O, et al. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion. Br J Cancer. 2014;110(11):2640–6. https://doi.org/10.1038/bjc.2014.237.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Canlorbe G, Bendifallah S, Laas E, Raimond E, Graesslin O, Hudry D, et al. Tumor size, an additional prognostic factor to include in low-risk endometrial cancer: results of a French multicenter study. Ann Surg Oncol. 2016;23(1):171–7. https://doi.org/10.1245/s10434-015-4583-3.

    Article  PubMed  Google Scholar 

  37. Jiang P, Jia M, Hu J, et al. Prognostic value of Ki67 in patients with stage 1-2 endometrial cancer: validation of the cut-off value of Ki67 as a predictive factor. Onco Targets Ther. 2020;13:10841–50. Published 2020 Oct 27. https://doi.org/10.2147/OTT.S274420.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Sasada S, Yunokawa M, Takehara Y, Ishikawa M, Ikeda S, Kato T, et al. Baseline risk of recurrence in stage I-II endometrial carcinoma. J Gynecol Oncol. 2018;29(1):e9. https://doi.org/10.3802/jgo.2018.29.e9.

    Article  PubMed  Google Scholar 

  39. Bishop EA, Java JJ, Moore KN, Walker JL. Pathologic and treatment outcomes among a geriatric population of endometrial cancer patients: an NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2. Int J Gynecol Cancer. 2017;27(4):730–7. https://doi.org/10.1097/IGC.0000000000000947.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Ouldamer L, Bendifallah S, Body G, et al. Predicting poor prognosis recurrence in women with endometrial cancer: a nomogram developed by the FRANCOGYN study group. Br J Cancer. 2016;115(11):1296–303. https://doi.org/10.1038/bjc.2016.337.

    Article  PubMed  PubMed Central  Google Scholar 

  41. AlHilli MM, Mariani A, Bakkum-Gamez JN, et al. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol. 2014;133(3):485–93. https://doi.org/10.1016/j.ygyno.2014.03.567.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Fujimoto T, Nanjyo H, Fukuda J, Nakamura A, Mizunuma H, Yaegashi N, et al. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence. Gynecol Oncol. 2009;112(2):342–7. https://doi.org/10.1016/j.ygyno.2008.10.019.

    Article  PubMed  Google Scholar 

  43. Bendifallah S, Canlorbe G, Huguet F, Coutant C, Hudry D, Graesslin O, et al. A risk scoring system to determine recurrence in early-stage type 1 endometrial cancer: a French multicentre study. Ann Surg Oncol. 2014;21(13):4239–45. https://doi.org/10.1245/s10434-014-3864-6.

    Article  PubMed  Google Scholar 

  44. Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res. 2016;22(16):4215–24. https://doi.org/10.1158/1078-0432.CCR-15-2878.

    Article  CAS  PubMed  Google Scholar 

  45. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. https://doi.org/10.1038/nature12113.

    Article  CAS  Google Scholar 

  46. Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29(5):1180–8. https://doi.org/10.1093/annonc/mdy058.

    Article  CAS  PubMed  Google Scholar 

  47. Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015;28(6):836–44. https://doi.org/10.1038/modpathol.2015.43.

    Article  CAS  PubMed  Google Scholar 

  48. Britton H, Huang L, Lum A, Leung S, Shum K, Kale M, et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol Oncol. 2019;153(3):487–95. https://doi.org/10.1016/j.ygyno.2019.03.098.

    Article  PubMed  Google Scholar 

  49. León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38(29):3388–97. https://doi.org/10.1200/JCO.20.00549.

    Article  PubMed  PubMed Central  Google Scholar 

  50. van den Heerik ASVM, Horeweg N, de Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. International Journal of Gynecologic Cancer. 2020. https://doi.org/10.1136/ijgc-2020-001822.

  51. van den Heerik ASVM, Horeweg N, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld GH, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020;30(12):2002–7. https://doi.org/10.1136/ijgc-2020-001929.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Huvila J, Laajala TD, Edqvist PH, Mardinoglu A, Talve L, Pontén F, et al. Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma. Gynecol Oncol. 2018;149(1):173–80. https://doi.org/10.1016/j.ygyno.2018.02.016.

    Article  CAS  PubMed  Google Scholar 

  53. Obata T, Nakamura M, Mizumoto Y, et al. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma. PLoS One. 2017;12(11):e0188641. Published 2017 Nov 30. https://doi.org/10.1371/journal.pone.0188641.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W, et al. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol. 2017;30(7):1032–41. https://doi.org/10.1038/modpathol.2017.15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Cosgrove CM, Cohn DE, Hampel H, Frankel WL, Jones D, McElroy JP, et al. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecol Oncol. 2017;146(3):588–95. https://doi.org/10.1016/j.ygyno.2017.07.003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Pasanen A, Tuomi T, Isola J, Staff S, Bützow R, Loukovaara M. L1 cell adhesion molecule as a predictor of disease-specific survival and patterns of relapse in endometrial cancer. Int J Gynecol Cancer. 2016;26(8):1465–71. https://doi.org/10.1097/IGC.0000000000000801.

    Article  PubMed  Google Scholar 

  57. Baxter E, Brennan DJ, McAlpine JN, et al. Improving response to progestin treatment of low-grade endometrial cancer. Int J Gynecol Cancer. 2020;30(11):1811–23. https://doi.org/10.1136/ijgc-2020-001309.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank Menna Kamel, MBBS, for her essential contribution to this manuscript. She assisted in designing the search strategy and participated in the screening process and study selection.

Funding

The authors are financially independent.

Availability of Data and Material

The data and material that support the findings of this study are available from the corresponding author upon request.

Code Availability

Not applicable.

Author information

Authors and Affiliations

  1. Gynecologic Oncology Unit, Ain Shams University Hospitals, 38 Ramsis St., Abbasseya, Cairo, 11591, Egypt

    Mohamed Laban

  2. Ain Shams University Hospitals, Cairo, Egypt

    Seif Tarek El-Swaify, Sara H. Ali, Mazen A. Refaat, Mohamed Sabbour & Nourhan Farrag

  3. The Department of Obstetrics and Gynecology, Ain Shams University, Cairo, Egypt

    Alaa Sayed Hassanin

Authors
  1. Mohamed Laban
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seif Tarek El-Swaify
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sara H. Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mazen A. Refaat
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohamed Sabbour
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nourhan Farrag
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alaa Sayed Hassanin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Laban.

Ethics declarations

Ethics Approval

There is a waiver as the review does not include any study on humans and/or animals.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 170 kb)

ESM 2

(DOCX 84 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Laban, M., El-Swaify, S.T., Ali, S.H. et al. The Prediction of Recurrence in Low-Risk Endometrial Cancer: Is It Time for a Paradigm Shift in Adjuvant Therapy?. Reprod. Sci. 29, 1068–1085 (2022). https://doi.org/10.1007/s43032-021-00565-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43032-021-00565-8

Keywords

Search

Navigation